Literature DB >> 21488893

Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

Sergio A Quezada1, Karl S Peggs, Tyler R Simpson, James P Allison.   

Abstract

The continual interaction of the immune system with a developing tumor is thought to result in the establishment of a dynamic state of equilibrium. This equilibrium depends on the balance between effector and regulatory T-cell compartments. Whereas regulatory T cells can infiltrate and accumulate within tumors, effector T cells fail to efficiently do so. Furthermore, effector T cells that do infiltrate the tumor become tightly controlled by different regulatory cellular subsets and inhibitory molecules. The outcome of this balance is critical to survival, and whereas in some cases the equilibrium can rapidly result in the elimination of the transformed cells by the immune system, in many other cases the tumor manages to escape immune control. In this review, we discuss relevant work focusing on the establishment of the intratumor balance, the dynamic changes in the populations of effector and regulatory T cells within the tumor, and the role of the tumor vasculature and its activation state in the recruitment of different T-cell subsets. Finally, we also discuss work associated to the manipulation of the immune response to tumors and its impact on the infiltration, accumulation, and function of tumor-reactive lymphocytes within the tumor microenvironment.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2011        PMID: 21488893      PMCID: PMC3727276          DOI: 10.1111/j.1600-065X.2011.01007.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  209 in total

1.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.

Authors:  Jackson G Egen; James P Allison
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

2.  CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction.

Authors:  P J Blair; J L Riley; B L Levine; K P Lee; N Craighead; T Francomano; S J Perfetto; G S Gray; B M Carreno; C H June
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

3.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

4.  Is immunological surveillance not a cell-mediated immune function?

Authors:  J Rygaard; C O Povlsen
Journal:  Transplantation       Date:  1974-01-01       Impact factor: 4.939

5.  Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Authors:  Gang Zhou; Charles G Drake; Hyam I Levitsky
Journal:  Blood       Date:  2005-09-22       Impact factor: 22.113

6.  Tumor gangliosides inhibit the tumor-specific immune response.

Authors:  R McKallip; R Li; S Ladisch
Journal:  J Immunol       Date:  1999-10-01       Impact factor: 5.422

7.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

8.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

Authors:  Luca Gattinoni; Christopher A Klebanoff; Douglas C Palmer; Claudia Wrzesinski; Keith Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 9.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

10.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.

Authors:  T Takahashi; Y Kuniyasu; M Toda; N Sakaguchi; M Itoh; M Iwata; J Shimizu; S Sakaguchi
Journal:  Int Immunol       Date:  1998-12       Impact factor: 4.823

View more
  105 in total

Review 1.  Targeted immunotherapy for acute myeloid leukemia.

Authors:  Sumithira Vasu; Michael A Caligiuri
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-11       Impact factor: 3.020

Review 2.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

3.  The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system.

Authors:  Samanthi Narayanan; David M Kranz
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

Review 4.  Mechanisms governing metastatic dormancy and reactivation.

Authors:  Filippo G Giancotti
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

5.  Systemic administration of β-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer.

Authors:  Mei Zhang; Liane Chun; Victor Sandoval; Hallie Graor; Jay Myers; Joseph Nthale; Peter Rauhe; Zachary Senders; Kevin Choong; Alex Y Huang; Julian Kim
Journal:  Oncoimmunology       Date:  2017-10-30       Impact factor: 8.110

Review 6.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

7.  The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells.

Authors:  Marilyn Giordano; Romain Roncagalli; Pierre Bourdely; Lionel Chasson; Michel Buferne; Sho Yamasaki; Rudi Beyaert; Geert van Loo; Nathalie Auphan-Anezin; Anne-Marie Schmitt-Verhulst; Grégory Verdeil
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

Review 8.  Deregulation of cell signaling in cancer.

Authors:  Filippo G Giancotti
Journal:  FEBS Lett       Date:  2014-02-20       Impact factor: 4.124

9.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Authors:  Ferdinandos Skoulidis; Lauren A Byers; Lixia Diao; Vassiliki A Papadimitrakopoulou; Pan Tong; Julie Izzo; Carmen Behrens; Humam Kadara; Edwin R Parra; Jaime Rodriguez Canales; Jianjun Zhang; Uma Giri; Jayanthi Gudikote; Maria A Cortez; Chao Yang; Youhong Fan; Michael Peyton; Luc Girard; Kevin R Coombes; Carlo Toniatti; Timothy P Heffernan; Murim Choi; Garrett M Frampton; Vincent Miller; John N Weinstein; Roy S Herbst; Kwok-Kin Wong; Jianhua Zhang; Padmanee Sharma; Gordon B Mills; Waun K Hong; John D Minna; James P Allison; Andrew Futreal; Jing Wang; Ignacio I Wistuba; John V Heymach
Journal:  Cancer Discov       Date:  2015-06-11       Impact factor: 39.397

10.  The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.

Authors:  Dewan Md Sakib Hossain; Priyanka Duttagupta; Marcin Kortylewski
Journal:  Ther Deliv       Date:  2015-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.